Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 405 Show results per page	View Search Criteria \| Help With Results


1.		PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				20050100 NCT00352703


2.		Oral Zinc Therapy for the Prevention of Mucositis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Supportive care, Treatment				Completed				18 to 70				Other				SHEBA-06-4196-MKM-CTIL NCT00449592


3.		Phase II/III Autologous Stem Cell Reinfusion Following ARA-C/BCNU for CML in Blast Crisis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								NCI-D82-018-544 DFCI-80051, DFCI-CML

Last Modified: 8/17/2007


4.		Phase II/III Adjuvant Therapy with High-Dose BCNU for High-Grade Malignant Glioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 65								VU-CNS-1 NCI-V85-0222

Last Modified: 5/1/1990


5.		Phase II/III Randomized Comparison of DTIC/BCNU/CDDP vs DTIC/BCNU/CDDP/TMX vs CDDP/TMX in Patients with Disseminated Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over								UCSD-88612 NCI-V89-0023

Last Modified: 12/6/2007 First Published: 9/24/2003


6.		Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				Under 30				NCI				COG-AHOD0121 NCT00070187, AHOD0121

Last Modified: 10/1/1997


7.		Phase III Randomized Study of Crisnatol Mesylate vs BCNU in the Consolidative Treatment of Glioblastoma Multiforme (Summary Last Modified 10/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Other				UTHSC-9235011015 SACI-IDD-003, UTHSC-IDD-003, NCI-V93-0321

Last Modified: 3/4/2008 First Published: 1/1/1994


8.		Phase III Randomized Study of Radiosurgery Followed by Conventional Radiotherapy with BCNU vs Conventional Radiotherapy with BCNU in Patients with Supratentorial Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				RTOG-9305 NCT00002545, RTOG-93-05

Last Modified: 5/4/2007 First Published: 1/1/1994


9.		NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Study of Melphalan/Total Body Irradiation with Peripheral Blood Stem Cell Rescue vs VBMCP (Vincristine/Carmustine/Melphalan/Cyclophosphamide/Prednisone) Following Standard Induction for Previously Untreated Symptomatic Multiple Myeloma, with Further Randomization for Major Responders to Interferon alfa vs Observation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				70 and under				NCI				SWOG-9321 CLB-9312, E-S9321, INT-0141, NCT00002548

Last Modified: 11/30/2007 First Published: 4/1/1994


10.		Phase III Randomized Study of Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone (VBMCP) Alone Versus VBMCP Alternating First With High-Dose Cyclophosphamide and Then With Interferon alfa in Patients With Previously Untreated Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-5A93 NCT00002556, E5A93

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute